RxDoctor Payments Data

Kathryn Krezoski Evans, DO

Family Medicine · Empire, MINPI 1194136721

Payments from drug & device makers

$1,353in general payments, 2019–2025

Across 63 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$369
  • AbbVie$331
  • Indivior Inc.$180
  • GSK$149
  • AstraZeneca$114
  • Merck$58
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$1,353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,353 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$36,882
Medicare patients
72
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$25,489
FarxigaDapagliflozin Propanediol21$25,114
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,761
MounjaroTirzepatide18$17,592
JardianceEmpagliflozin16$15,001
XareltoRivaroxaban12$6,666
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$4,836
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,465
Atorvastatin Calcium161$2,834
Levothyroxine Sodium152$2,575
Albuterol Sulfate HfaAlbuterol Sulfate47$1,314
Losartan Potassium57$1,291
Pantoprazole Sodium32$1,045
Estradiol11$954
Metoprolol Succinate32$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$25,48929 claims
AstraZenecaFarxiga$114$25,11421 claims
GSKTrelegy Ellipta, Shingrix$149$23,22643 claims
Lilly USA, LLCMounjaro$15$17,59218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Empire

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →